The exchangeability MR assumption was tested using genetic colocalization between SGLT2 inhibition and prostate cancer (Figure S2), where we observed evidence of colocalization of the two traits in the SLC5A2 region (colocalization probability = 72%; Table S8). The gene discussed is SLC5A2; the disease is prostate carcinoma.